Overview

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
The main purposes of this study are to evaluate the safety and tolerability of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza.
Phase:
Phase 3
Details
Lead Sponsor:
ModernaTX, Inc.